Fibrosis regression induced by intravenous gammaglobulin treatment

H Amital, E Rewald, Y Levy, Y Bar-Dayan, Rolf Manthorpe, P Engervall, Y Sherer, P Langevitz, Y Shoenfeld

Research output: Contribution to journalArticlepeer-review

49 Citations (SciVal)


Objectives: To review case histories of patients in whom fibrosis played a significant role in the pathogenesis of their disease, and to determine whether intravenous gammaglobulin (IVIg) contributed to the regression of their fibrotic condition. Methods: Eight patients with excess fibrotic reaction in the course of diverse diseases were analysed; a tendency that reverted with different IVIg treatment options. Myelofibrosis was predominant in three patients (a patient with a myeloproliferative syndrome, one with systemic lupus erythematosus, and one with Sjogren's syndrome). Three patients had scleroderma as their main feature, one patient had hepatitis C cirrhosis, and one had idiopathic thrombocytopenic purpura. Results: Fibrotic excess was reduced in all the patients by IVIg treatment. In five patients the disease as a whole benefited from the infusion of immunoglobulins. Conclusion: IVIg may enhance resorption of fibrosis and promote healing in patients with fibrotic associated disorders.
Original languageEnglish
Pages (from-to)175-177
JournalAnnals of the Rheumatic Diseases
Issue number2
Publication statusPublished - 2003

Subject classification (UKÄ)

  • Rheumatology and Autoimmunity


Dive into the research topics of 'Fibrosis regression induced by intravenous gammaglobulin treatment'. Together they form a unique fingerprint.

Cite this